Abstract: The present invention relates to an aqueous pharmaceutical composition comprising the P2Y12 receptor antagonist 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester and a pharmaceutically acceptable buffer and its use as a medicament by parenteral administration.

Abstract: The invention relates to crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one, processes for the preparation thereof, pharmaceutical compositions containing said crystalline forms, and their use as compounds improving vascular function and as immunomodulating agents, either alone or in combination with other active compounds or therapies.

Abstract: The invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt and a process for its preparation. Further, the present invention relates to the use of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt alone or in combination with other compounds. Further, the present invention relates to formulations of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt in the preparation of pharmaceutical compositions. The invention also relates to the use of such sulfate salts in formulations as neurohormonal antagonists.

Abstract: The invention relates to crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one, processes for the preparation thereof, pharmaceutical compositions containing said crystalline forms, and their use as compounds improving vascular function and as immunomodulating agents, either alone or in combination with other active compounds or therapies.

Abstract: The invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt and a process for its preparation. Further, the present invention relates to the use of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt alone or in combination with other compounds. Further, the present invention relates to formulations of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt in the preparation of pharmaceutical compositions. The invention also relates to the use of such sulfate salts in formulations as neurohormonal antagonists.

Abstract: A coaxial cable stripper, consisting of:—a cutting unit (1) comprising cutting means (7) for a plurality of sheaths, said cutting unit (1) being designed to surround a cable (5) and cut its sheaths simultaneously by rotation of said cutting means (7) about the cable (5),—an intermediate unit (2) designed to surround said cable (5) and comprising means (6, 29-31) for adjusting the rotation of said cutting means (7),—a fixing unit (3) comprising fixing means (8) for said cable (5), the three units (1-3) being adjacent to one another and aligned along a common axis defined by said cable (5).

Abstract: In a plug arrangement for optical waveguides, there is mounted on the end of the cable accommodating the optical waveguide a cable fixing sleeve that is bonded to the outside of the cable. The ends of the plastic fibers of the optical waveguide cladding are brought out of the cable end and laid back onto the external surface of the bonded-on cable fixing sleeve and a further sleeve being pushed onto said cable fixing sleeve, with the plastic fibers of the optical waveguide cladding being clamped and bonded between the two sleeves.

Abstract: Control device (1) for an electrical household appliance for the preparation of infusion beverages, having a housing (2) enclosing a reservoir (3) for cold water, a heating plate (4) supported an infusion collector (5), a water heater (6) connected thermally to the plate (4) and having a conduit (6') connected to the cold water reservoir (3) and a rising conduit (6") connected to a water pipe (7) of an infusion filter (8) disposed above the infusion collector (5). An electrical heating resistance (9) for the water heater (6) is connected to an electrical supply circuit (10) switchingly controlled by the device. The device supplies the electrical resistance (9) in a first phase intermittently by current pulses of predetermined duration, separated by pause times also of predetermined duration, and in a second phase supplies the electrical resistance (9) with a direct current.

Abstract: The system for testing the diffusion behavior of a substance comprises a donor compartment detachably mounted on a holding member of a rotor, rotatably around a vertical axis, said donor compartment being bounded at its bottom by a membrane effective to separate the donor compartment from an acceptor compartment. The membrane comprises a flexible carrier of a bio-compatible, lifeless, light permeable material, on which cells constituting a monocellular layer have been cultivated, for example. By determining the time dependent variation of the quantity of a substance passing through the membrane by diffusion, it is possible to determine the coefficient of diffusion and/or the coefficient of permeability of the membrane and of the cell culture provided thereon. By suitable selection of the cells, conditions may be created that closely resemble those that occur during the absorption of the respective substance through the biophase of a living organism.